News | October 04, 2024
SK pharmteco invests US$ 260 million to expand global small molecule, peptide production
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Establishing Asymchem’s first manufacturing footprint in Europe
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Establishment of 220 smart classrooms across Uttar Pradesh, Uttarakhand, and Himachal Pradesh
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Subscribe To Our Newsletter & Stay Updated
